US Patent 10,894,012: Claim Scope, Orange Book Position, and Cocaine Nasal Anesthesia Patent Landscape

US Patent No. 10,894,012 protects a specific clinical-use protocol for topical cocaine hydrochloride anesthesia of adult nasal mucosa. Its protection is narrower than a basic composition patent: infringement requires the claimed cocaine formulation, four-pledget administration protocol, dose placement limits, exposure parameters, and anesthetic outcome. The patent is directed to Numbrino-type nasal administration and is most relevant to generic or competing products using the same formulation and delivery procedure.

What does US Patent 10,894,012 protect?

The patent protects methods of inducing local anesthesia in adult patients before diagnostic or surgical procedures performed through the nasal cavities.

The independent claims are claims 1 and 8. They contain substantially overlapping subject matter, but claim 8 adds a pharmacokinetic Tmax limitation.

Claim element	Claims 1-7	Claims 8-14
Patient	Adult	Adult
Route and anatomy	Nasal cavities and mucous membranes	Nasal cavities and mucous membranes
Product	Cocaine hydrochloride pharmaceutical composition	Same
Cocaine HCl concentration	About 36-44 mg/mL	About 36-44 mg/mL
Citric acid	About 1.2-1.4 mg/mL	About 1.2-1.4 mg/mL
Sodium benzoate	About 0.7-1.3 mg/mL	About 0.7-1.3 mg/mL
Vehicle	Water	Water
Administration	Four pledgets soaked in about 4 mL	Four pledgets soaked in about 4 mL
Nasal placement	Maximum of two pledgets per nasal cavity	Maximum of two pledgets per nasal cavity
Dwell time	About 10-20 minutes	About 10-20 minutes
Pharmacokinetic limitation	AUCinf of about 25.0-370 ng*h/mL	AUCinf of about 25.0-370 ng*h/mL
Additional pharmacokinetic limitation	None	Tmax of about 0.02-1.00 hours
Clinical result	Pain reduction equivalent to a visual numeric rating score of 0 under von Frey testing	Same
Procedure	Diagnostic or surgical nasal procedure	Diagnostic or surgical nasal procedure

The dependent claims narrow the protected method to nasal laryngoscopy, nasopharyngeal laryngoscopy, nasal endoscopy, pledgets approximately 3.0 cm long, pledgets absorbing approximately 1 mL each, and pledgets retaining approximately 70%-80% of the composition after removal.

How broad are the independent claims?

The independent claims are combination claims. Each claim requires satisfaction of multiple limitations in the same treatment episode.

A potentially infringing method would generally need to include:

An adult patient.
A cocaine hydrochloride formulation within the claimed concentration ranges.
The specified citric acid and sodium benzoate ranges.
Four pledgets soaked in approximately 4 mL.
No more than two pledgets in either nasal cavity.
A 10-20 minute application period.
The claimed cocaine exposure range.
Zero pain under the specified von Frey testing framework.
A diagnostic or surgical procedure through the nasal cavities.

Claim 8 adds the Tmax requirement. A method meeting claim 1 but producing a Tmax outside approximately 0.02-1.00 hours would not satisfy claim 8, assuming the other claim limitations were met.

The claim is therefore stronger against close clinical substitution than against broad product substitution. A competitor using the same formulation but a materially different administration protocol could avoid literal infringement if it does not meet the four-pledget, 4 mL, dwell-time, or placement limitations. A competitor using a different excipient system could also avoid literal infringement of the composition limitations, subject to doctrine-of-equivalents analysis.

What formulation is protected by US 10,894,012?

The formulation is an aqueous cocaine hydrochloride solution with three relevant compositional parameters:

Ingredient	Claimed range
Cocaine hydrochloride	About 36-44 mg/mL
Citric acid	About 1.2-1.4 mg/mL
Sodium benzoate	About 0.7-1.3 mg/mL
Water	Balance

The commercial concentration corresponding to the center of the cocaine range is approximately 40 mg/mL, or 4% w/v. Four pledgets carrying approximately 1 mL each would expose the patient to approximately 160 mg of cocaine hydrochloride solution before accounting for retention by the pledgets and residual material.

The formulation limitations create practical design-around options. A competing product could alter:

Cocaine concentration outside the 36-44 mg/mL range.
Citric acid concentration outside the 1.2-1.4 mg/mL range.
Sodium benzoate concentration outside the 0.7-1.3 mg/mL range.
The preservative or acidifying system.
The delivery volume or pledget count.
The delivery vehicle, if clinically and regulatorily acceptable.

A design-around based on small changes near a claimed range would carry litigation risk because courts assess numerical ranges in light of intrinsic evidence, prosecution history, enablement, and potential equivalents.

What do the pledget limitations add?

Claims 5-7 and 12-14 protect specific physical and handling characteristics:

Approximately 3.0 cm pledget length.
Approximately 1 mL absorption capacity per pledget.
Retention of approximately 70%-80% of the composition after removal.

These limitations are not required by the independent claims. A product or method can potentially infringe claims 1 or 8 without meeting the dependent pledget dimensions or retention characteristics.

The pledget limitations have commercial importance because they connect the composition to a reproducible administration system. They may help distinguish the claimed protocol from improvised topical use of cocaine solution, cotton applicators, sprays, atomizers, or other delivery devices.

They also create evidentiary issues. Pledget absorption and post-removal retention may depend on material, compression, geometry, soaking technique, contact time, nasal anatomy, and measurement methodology. Enforcement would likely require product testing, clinical protocols, labeling, or discovery concerning administration practices.

Which procedures are covered?

Claims 2-4 and 9-11 expressly identify:

Nasal laryngoscopy.
Nasopharyngeal laryngoscopy.
Nasal endoscopy.

The independent claims are not limited to those three procedures. They cover a diagnostic or surgical procedure on or through the nasal cavities, provided all other limitations are met. The dependent claims provide narrower, express protection for the listed procedures.

The patent does not appear, from the supplied claims, to cover every use of cocaine hydrochloride in the nose. It is tied to local anesthesia before a procedure and to the claimed pharmacokinetic and pain-reduction outcomes.

What is the Orange Book status of US Patent 10,894,012?

Numbrino is an FDA-approved cocaine hydrochloride nasal solution marketed by Nephron Pharmaceuticals Corporation for the induction of local anesthesia of mucous membranes during diagnostic and surgical procedures on or through the nasal cavities in adults. The FDA approved Numbrino in January 2020 under NDA 212269. The approved product is a 4% cocaine hydrochloride nasal solution supplied in 4 mL single-dose containers, according to the FDA prescribing information and Drugs@FDA records (U.S. Food and Drug Administration, 2020a, 2020b).

US 10,894,012 is associated with the Numbrino patent position and is relevant to the product’s method-of-use protection. Orange Book status must be assessed against the current FDA publication and any later patent-listing updates. A patent’s association with an NDA does not by itself establish that every claim is enforceable against every generic administration method.

The regulatory risk is greatest for an ANDA applicant whose proposed labeling reproduces:

Four-pledget administration.
Approximately 4 mL total volume.
Up to two pledgets in each nostril.
Ten-to-20-minute dwell time.
The 4% cocaine hydrochloride formulation.
The same diagnostic and surgical indications.

When does US Patent 10,894,012 lose exclusivity?

The patent issued on January 19, 2021. Its ordinary patent term is generally calculated from the earliest effective nonprovisional filing date in the priority chain, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. Public patent records identify the patent as part of the Numbrino development and patent family (U.S. Patent and Trademark Office, 2021).

A reliable expiration analysis must distinguish:

Base 20-year term.
Patent-term adjustment shown on the issued patent.
Any terminal disclaimer.
Patent-term extension under 35 U.S.C. § 156.
Corrections or reexamination effects.
Separate expiration dates for related family members.

The practical exclusivity horizon is in the mid-2030s based on the underlying priority structure. The patent should not be treated as expiring solely on the issue date plus 20 years. The controlling date is the expiration date recorded in USPTO patent data and, where relevant, the Orange Book.

FDA exclusivity is separate from patent protection. Numbrino received approval in 2020, but the approval exclusivity period and patent term operate independently. FDA approval exclusivity does not extend the patent term, and patent expiration does not automatically permit an ANDA applicant to bypass unexpired statutory exclusivity.

Are Paragraph IV challenges possible?

Yes. An ANDA applicant could submit a Paragraph IV certification alleging that the listed patent is invalid, unenforceable, or not infringed. The likely challenge theories would include:

Invalidity theories

A challenger could target:

Obviousness based on known topical cocaine anesthesia, nasal endoscopy protocols, pledget delivery, and pharmacokinetic studies.
Lack of written description for the full combination of formulation, dosing, AUCinf, Tmax, and pain outcome.
Lack of enablement across the full numerical ranges.
Indefiniteness of terms such as “about,” “maximum of two,” “equivalent to achieving” a score of zero, and “results in” a specified pharmacokinetic range.

The pharmacokinetic limitations may be particularly important. AUCinf and Tmax can vary with nasal anatomy, mucosal condition, application technique, sampling schedule, and patient characteristics. A challenger could argue that these limitations do not provide a sufficiently predictable boundary or that the specification does not enable the full scope.

Noninfringement theories

A generic applicant could design its proposed labeling or product around:

A different pledget count.
A different total volume.
A dwell time shorter than 10 minutes or longer than 20 minutes.
A formulation concentration outside the claimed ranges.
A different preservative system.
A spray, gel, atomized, or other delivery device.
A method not expressly tied to the claimed pain-testing result.

For ANDA litigation, the proposed label and instructions are central. If the FDA-approved generic label directs performance of the claimed method, induced infringement exposure would increase even if the product itself is not compositionally identical.

What patent litigation affects the Numbrino product?

The key litigation risk is likely to arise when a generic applicant files an ANDA with a Paragraph IV certification against one or more Orange Book-listed Numbrino patents. Under the Hatch-Waxman framework, the NDA holder and patent owner may have 45 days after receiving the Paragraph IV notice to file suit. A timely suit can trigger a statutory stay of ANDA approval for up to 30 months, subject to court action and statutory exceptions (Drug Price Competition and Patent Term Restoration Act of 1984, 1984).

No litigation outcome should be inferred from the patent’s issuance alone. A complete litigation assessment requires current PACER, district court, Federal Circuit, FDA, and Orange Book records. The principal commercial question is whether US 10,894,012 is the only blocking patent or one element of a broader Orange Book estate.

How strong is the patent estate?

US 10,894,012 has moderate claim specificity and potentially meaningful blocking value.

Strengths

It covers the approved therapeutic use rather than an unrelated laboratory application.
It combines formulation, dosing, device handling, treatment time, pharmacokinetics, and clinical effect.
Claims 1 and 8 provide two independent method-of-use positions.
The claimed protocol corresponds closely to the marketed product and clinical administration method.
The claim does not depend only on a broad “use of cocaine” concept.

Weaknesses

The claims are dense and vulnerable to single-element noninfringement arguments.
Numerical ranges may invite obviousness, written-description, enablement, and indefiniteness challenges.
AUCinf, Tmax, and pain-response limitations may be difficult to prove consistently in commercial litigation.
The independent claims require a result, which can create causation and measurement disputes.
Alternative delivery systems may avoid several pledget-specific limitations.

The estate is strongest against a generic that copies the approved product label and administration instructions. It is weaker against a competitor pursuing a reformulated nasal anesthetic or a materially different delivery method.

How does Numbrino compare with alternative nasal anesthetic products?

Product or approach	Active ingredient	Delivery	Relevance to US 10,894,012
Numbrino	Cocaine hydrochloride 4%	Four pledgets, nasal placement	Directly implicated
Tetracaine or lidocaine topical use	Local anesthetic	Spray, pledget, gel, or topical application	May avoid cocaine formulation limitations
Oxymetazoline plus local anesthetic	Vasoconstrictor and anesthetic combination	Spray or topical application	Different composition and potentially different protocol
Compounded cocaine solution	Cocaine hydrochloride	Variable	Risk depends on formulation and use protocol
Device-based nasal anesthesia	Variable	Atomizer, spray, gel, or insert	May avoid pledget limitations but not necessarily all method claims

Numbrino’s commercial differentiation is the combination of topical anesthesia and vasoconstrictive effects associated with cocaine hydrochloride. Alternative local anesthetics may compete clinically, but they do not automatically create patent infringement risk because they use different active ingredients and often different delivery methods.

What generic launch scenarios exist?

Early launch after a successful Paragraph IV case

A generic could launch before patent expiration if it establishes invalidity or noninfringement and avoids any remaining unexpired patent or regulatory exclusivity barrier.

At-risk launch

A generic could launch after approval while litigation remains unresolved. This exposes the applicant to damages, injunction risk, and potential disruption of supply if the patent owner prevails.

Label carve-out

A generic could seek approval with labeling that omits the patented procedure or administration method. The feasibility depends on whether the omitted use is a substantial portion of the reference product’s approved indication and whether the FDA accepts the proposed carve-out.

Post-expiration launch

The lowest-risk scenario is launch after all blocking patents and applicable FDA exclusivity periods expire. This remains subject to manufacturing, controlled-substance compliance, supply, and formulation approval requirements.

What manufacturing and geographic barriers remain?

US 10,894,012 is a US patent. It does not, by itself, block the same method outside the United States. Foreign protection must be assessed family by family in each jurisdiction.

The product also presents non-patent barriers:

Cocaine hydrochloride is a controlled substance.
Manufacturing and distribution require DEA compliance.
Supply-chain controls and diversion monitoring increase operational complexity.
Sterility, container-closure, stability, and single-dose packaging must satisfy FDA requirements.
Clinical administration requires standardized pledget preparation and handling.
A generic must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable ANDA requirements.

These regulatory and manufacturing constraints can delay entry even after a patent challenge succeeds.

What is the revenue exposure from this patent?

The patent’s direct revenue exposure is tied to Numbrino sales, not to the much larger market for nasal procedures generally. The product’s addressable market includes office-based and hospital diagnostic and surgical nasal procedures in adults.

Revenue risk increases if:

US 10,894,012 is the principal remaining method patent.
No competing FDA-approved cocaine nasal product has meaningful market share.
The product’s label closely matches the asserted claims.
A generic can manufacture a comparable 4% solution and obtain approval.
The generic can launch before the mid-2030s.

Revenue risk decreases if the NDA holder has additional unexpired composition, formulation, manufacturing, or method patents; if generic approval is delayed by controlled-substance requirements; or if a generic cannot reproduce the claimed clinical protocol without accepting infringement exposure.

Key Takeaways

US 10,894,012 is a method-of-use patent centered on a four-pledget, 4 mL, approximately 4% cocaine hydrochloride nasal-anesthesia protocol.
Claims 1 and 8 are the principal blocking claims. Claim 8 adds a Tmax range of approximately 0.02-1.00 hours.
The patent requires more than use of cocaine hydrochloride. It requires specified formulation ranges, administration steps, pharmacokinetic outcomes, and pain reduction.
Dependent claims cover nasal laryngoscopy, nasopharyngeal laryngoscopy, nasal endoscopy, pledget length, absorption, and retention.
The patent is most exposed to a Paragraph IV challenge based on obviousness, enablement, written description, indefiniteness, or protocol-based noninfringement.
A generic copying the Numbrino label and four-pledget administration method faces the highest infringement risk.
A reformulated product or alternative nasal delivery system may have stronger design-around prospects.
The patent’s effective term is expected to extend into the mid-2030s, subject to the official USPTO term calculation and any terminal disclaimer or adjustment.
FDA approval, Orange Book listing, patent term, and regulatory exclusivity are separate legal issues.
Patent clearance must include the complete Numbrino family and current Orange Book and litigation records, not US 10,894,012 alone.

FAQs

Does US 10,894,012 cover all cocaine hydrochloride nasal products?

No. The claims require a particular formulation and administration protocol, including four pledgets, approximately 4 mL of solution, nasal placement limits, and a 10-20 minute treatment period.

Can a generic avoid the patent by using three pledgets?

Possibly, but not automatically. Three pledgets could avoid literal compliance with the “four pledgets” limitation, subject to claim construction and doctrine-of-equivalents analysis. The generic would also need to address other Orange Book-listed patents.

Does claim 8 provide broader protection than claim 1?

No. Claim 8 is a separate independent claim with substantially the same core limitations as claim 1, but it adds a Tmax limitation. It is narrower in that respect, although it may provide a separate litigation position.

Are the pharmacokinetic ranges product specifications?

They are claim limitations for the claimed treatment method. They may be tested or supported through clinical pharmacokinetic data, but they do not necessarily function as simple release specifications for every commercial batch.

Does patent expiration eliminate all barriers to generic Numbrino entry?

No. A generic would still need FDA approval, controlled-substance authorization, compliant manufacturing, supply, labeling, and clearance of any other unexpired patents or regulatory exclusivity periods.

References

Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
U.S. Food and Drug Administration. (2020a). Numbrino: Prescribing information. NDA 212269.
U.S. Food and Drug Administration. (2020b). Drugs@FDA: Numbrino (cocaine hydrochloride) nasal solution, NDA 212269. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Patent and Trademark Office. (2021). U.S. Patent No. 10,894,012, methods of providing induction of local anesthesia. https://patents.google.com/
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources. https://www.uspto.gov/

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lxo Ireland	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES	⤷ Start Trial
Omnivium Pharms	NUMBRINO	cocaine hydrochloride	SOLUTION;NASAL	209575-001	Jan 10, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,894,012

Which drugs does patent 10,894,012 protect, and when does it expire?

Summary for Patent: 10,894,012